Share via Email

* Email To: (Separate multiple addresses with a semicolon)
* Your Name:
* Email From: (Your IP Address is 3.137.171.71)
* Email Subject: (personalize your message)


Email Content:

Plant-Based COVID Vaccines Under Evaluation

 04/03/2021

A joint venture between Medicago and GlaxoSmithKline will commence a Phase 3 study of a unique vaccine in which the spike protein of SARS-CoV-2 is propagated in tobacco plants using a specific bacterial vector.  Medicago extracts the virus-like particles that are then purified.  GlaxoSmithKline will provide the adjuvant necessary to enhance stimulation of immunity.